Global Information
회사소개 | 문의 | 위시리스트

세계의 담낭암 치료제 시장(2019-2023년)

Gallbladder Cancer Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2019년 08월 상품 코드 906356
페이지 정보 영문 133 Pages
가격
US $ 2,500 ₩ 2,987,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,584,000 PDF by E-mail (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,779,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,974,000 PDF by E-mail (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 담낭암 치료제 시장(2019-2023년) Gallbladder Cancer Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023
발행일 : 2019년 08월 페이지 정보 : 영문 133 Pages

세계의 담낭암 치료제(Gallbladder Cancer Therapeutics) 시장은 개발도상국의 높은 담낭암 발생률, 담낭암의 위험인자 증가, 치료 접근으로서의 화학요법 사용 등이 성장 촉진요인으로 작용하며, 예측 기간 중 약 5%의 CAGR로 확대될 전망입니다. 그러나 화학요법에 관련된 부작용, 담낭암의 진단 항원 결여, 선진국의 낮은 질환 발생률 등의 불안정 요인이 예측 기간 중 세계 담낭암 치료제 산업의 성장을 저해할 가능성이 있습니다.

세계의 담낭암 치료제 시장에 대해 조사분석했으며, 시장 규모 및 성장률, 시장 동향, 시장 성장 촉진요인·과제, 시장 기회 검증 및 주요 벤더 등에 관한 정보를 정리하여 전해드립니다.

목차

제1장 개요

제2장 조사 범위

  • 서론 1
  • 서론 2
  • 달러의 통화 환산율

제3장 시장 상황

  • 시장 에코시스템
  • 시장의 특징
  • 시장 세분화 분석

제4장 시장 규모

  • 시장의 정의
  • 시장 규모(2018년)
  • 시장 규모 및 예측(2018-2023년)

제5장 Five Forces 분석

  • 바이어의 교섭력
  • 공급업체의 교섭력
  • 신규 진출의 위협
  • 대용품의 위협
  • 경쟁 상대의 위협
  • 시장 현황

제6장 파이프라인 분석

제7장 시장 세분화 : 종류별

  • 시장 세분화 : 종류별
  • 종류별 비교 : 시장 규모 및 예측(2018-2023년)
  • 병용요법
  • 단독요법
  • 시장 기회 : 종류별

제8장 고객 상황

제9장 지역별 상황

  • 지역별 세분화
  • 지역별 비교 : 시장 규모 및 예측(2018-2023년)
  • 북미
  • 유럽
  • 아시아
  • 기타 지역
  • 주요 국가
  • 시장 기회

제10장 의사결정 프레임워크

제11장 성장요인과 과제

  • 시장 성장요인
  • 시장이 해결해야 할 과제

제12장 시장 동향

  • 강력한 파이프라인
  • 표적치료의 출현
  • 전략적 제휴

제13장 벤더 구도

  • 개요
  • 창조적 파괴 상황
  • 경쟁 시나리오

제14장 벤더 분석

  • 대상 벤더
  • 벤더 분류
  • 벤더의 시장 포지셔닝
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Sanofi

제15장 부록

  • 조사 방법
  • 약어 리스트
  • 벤더의 시장 포지셔닝 정의

제16장 TECHNAVIO 소개

KSA 19.08.23

About this market

Technavio's gallbladder cancer therapeutics market considers sales from both combination therapy and monotherapy. Our analysis also considers the sales of gallbladder cancer therapeutics in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high therapeutic efficacy of these drugs will play a significant role in the combination therapy segment to maintain its market position. Also, our global gallbladder cancer therapeutics market report looks at factors such as strong incidence of gallbladder cancer in developing countries, rising risk factors for gall bladder cancer, and use of chemotherapy as a therapeutic approach. However, uncertainties in the side effect associated with chemotherapy, lack of diagnostic antigens for gallbladder cancer, and low incidence rate of disease in developed countries may hamper the growth of the global gallbladder cancer therapeutics industry over the forecast period.

Overview

Rising risk factors for gallbladder cancer

Rise in the occurrence of cholelithiasis, chronic inflammation, and gall bladder polyps will increase the risk of developing gall bladder cancer, inducing the demand gallbladder cancer therapeutics. The rising availability of financial assistance programs is further helping patients in availing these high-cost treatments. This will lead to the expansion of the global gallbladder cancer therapeutics market at a CAGR of almost 5% during the forecast period.

The advent of targeted therapy

The global gallbladder cancer therapeutics market is witnessing the advent of immunotherapy as a potential therapeutic for the treatment of biliary tract cancer, including gallbladder cancer. The ongoing research in this is expected to facilitate the approval process of this drug. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global gallbladder cancer therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global gallbladder cancer therapeutics market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gallbladder cancer therapeutics manufacturers, that include Bristol-Myers Squibb Co., Eli Lilly, and Co., F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi.

Also, the gallbladder cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Strong pipeline
  • Advent of targeted therapy
  • Strategic alliances

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Sanofi

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Some late-stage molecules for biliary tract cancer and global gallbladder cancer
  • Exhibit 19: Type - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by type
  • Exhibit 21: Combination therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Combination therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Monotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Monotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by type
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in North America
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in Europe
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Asia
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in ROW
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: Incidence rate of gallbladder cancer in various developing countries - 2015
  • Exhibit 44: Frequency of side effects associated with chemotherapy
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: Bristol-Myers Squibb Co. - Vendor overview
  • Exhibit 52: Bristol-Myers Squibb Co. - Business segments
  • Exhibit 53: Bristol-Myers Squibb Co. - Organizational developments
  • Exhibit 54: Bristol-Myers Squibb Co. - Geographic focus
  • Exhibit 55: Bristol-Myers Squibb Co. - Key offerings
  • Exhibit 56: Bristol-Myers Squibb Co. - Key customers
  • Exhibit 57: Eli Lilly and Co. - Vendor overview
  • Exhibit 58: Eli Lilly and Co. - Business segments
  • Exhibit 59: Eli Lilly and Co. - Organizational developments
  • Exhibit 60: Eli Lilly and Co. - Geographic focus
  • Exhibit 61: Eli Lilly and Co. - Segment focus
  • Exhibit 62: Eli Lilly and Co. - Key offerings
  • Exhibit 63: Eli Lilly and Co. - Key customers
  • Exhibit 64: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 65: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 66: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 67: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 68: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 69: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 70: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 71: Pfizer Inc. - Vendor overview
  • Exhibit 72: Pfizer Inc. - Business segments
  • Exhibit 73: Pfizer Inc. - Organizational developments
  • Exhibit 74: Pfizer Inc. - Geographic focus
  • Exhibit 75: Pfizer Inc. - Segment focus
  • Exhibit 76: Pfizer Inc. - Key offerings
  • Exhibit 77: Pfizer Inc. - Key customers
  • Exhibit 78: Sanofi - Vendor overview
  • Exhibit 79: Sanofi - Business segments
  • Exhibit 80: Sanofi - Organizational developments
  • Exhibit 81: Sanofi - Geographic focus
  • Exhibit 82: Sanofi - Segment focus
  • Exhibit 83: Sanofi - Key offerings
  • Exhibit 84: Sanofi - Key customers
  • Exhibit 85: Validation techniques employed for market sizing
  • Exhibit 86: Definition of market positioning of vendors
Back to Top
전화 문의
F A Q